Skip to main content
. 2017 Apr 7;8(21):35205–35221. doi: 10.18632/oncotarget.16925

Table 1. Pretreatment characteristics and univariate associations with pCR.

pCR n = 20 non-pCR n = 58 p
Clinical data
Median age (years) 48 52 ns
SBR grade
I–II 30% 21% ns
III 70% 79% ns
Chemotherapy regimen
SIM 25% 17% ns
4 cycles EC - 4 cycles D 65% 69% ns
Taxane-based 10% 14% ns
Pathological data
CD133-expressing cells 3.5% (± 0.9) 10.4% (± 4) < 0.01
ALDH1-expressing cells 2.6% (± 2.8) 8.6% (± 5.9) < 0.01
CD146-expressing cells 6.3% (± 3.8) 17.8% (± 6.3) < 0.01
CD133/ALDH1
co-expressing cells 1.2% (± 1.6) 6.3% (± 3.6) < 0.01
CD133/CD146
co-expressing cells 3.1% (± 1.1) 9.2% (± 3.1) < 0.01
Necrosis
Yes 25% 74% < 0.01
No 75% 26% < 0.01

SBR: Scarff, Bloom and Richardson grading system.

SIM: Dose-dense epirubicin-cyclophosphamide-based regimen (Lehmann-Che et al., 2010).

EC = epirubicin (100 mg/m<sup>2</sup>/cycle) and cyclophosphamide (500 mg/m<sup>2</sup>/cycle), one cycle every 21 days.

D = docetaxel (100 mg/m<sup>2</sup>/cycle), one cycle every 21 days.